Does satelizumab (Anshiping) treat myelitis?

Satralizumab (Satralizumab) is used to treat idiopathic neuromyelitis optica (NMOSD). NMOSD is a rare autoimmune disease that primarily affects the central nervous system, including the spinal cord and optic nerve. Satrolizumab reduces the number of attacks in NMOSD patients by suppressing specific immune responses and can help control the progression of the disease. However, for specific treatment options and medication use, patients are advised to consult their physician for detailed information and guidance.

Two major studies have shown that satelizumab can effectively prolong the time between relapses in patients with NMOSD The first study involved 55 patients aged 12 and older with AQP4 antibodies who were receiving immunosuppressive therapy. The study showed that 92% of patients who received immunosuppressive therapy were relapse-free after 48 weeks, compared with 60% of patients who received placebo (dummy) therapy and immunosuppressive therapy. Another study involving 64 adults with AQP4 antibodies showed that patients taking satelizumab were relapse-free after 48 weeks, compared with 55% of those taking a placebo.

The original drug satlizumab has been launched in China, sold under the brand name Anshiping, and is included in medical insurance. Only patients who meet the indications can be reimbursed. The specification is120mg (1ml) per box The price may be more than RMB 10,000, which is still relatively expensive; the price of each box of the original drug Saterizumab sold overseas is more than $10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drug sold domestically and abroad are basically the same. There are currently no generic versions of satlizumab available on the market.